Establishment Labs Secures $300M Refinancing Deal with Oaktree
Event summary
- Establishment Labs refinanced its debt with a $300M senior secured term loan from Oaktree Capital Management.
- The facility includes a $265M tranche to refinance existing debt and a $35M tranche for future growth initiatives.
- The loan matures in 2031 with no amortization, offering financial flexibility.
- Oaktree has committed over $6B across 44 investments in the healthcare sector since 2020.
The big picture
Establishment Labs' refinancing deal with Oaktree Capital Management underscores the company's focus on strengthening its capital structure and supporting future growth. The $300M facility provides extended maturity and financial flexibility, aligning with broader trends in the medical technology sector where strategic financing is crucial for innovation and market expansion. Oaktree's continued support reflects confidence in Establishment Labs' fundamentals and growth potential.
What we're watching
- Financial Flexibility
- How the additional capital will support Establishment Labs' strategic growth initiatives and operational needs.
- Market Expansion
- The pace at which Establishment Labs can scale its products, particularly Motiva implants, in the U.S. market.
- Operational Performance
- Whether Establishment Labs can achieve positive free cash flow in the second half of 2026 as projected.
Related topics